We are live on
!
Find out more
BAMCO Inc Portfolio holdings
AUM
$66.6B
Turnover
22.96%
1-Year Est. Return
7.35%
This Fund
S&P 500
This Quarter
Est. Return
+7.81%
1 Year Est. Return
+7.35%
3 Year Est. Return
+62.2%
5 Year Est. Return
+84.27%
10 Year Est. Return
+776.55%
AUM
$37.7B
AUM Growth
+$825M
(+2.2%)
Cap. Flow
-$555M
Cap. Flow
% of AUM
-1.47%
Top 10 Holdings %
Top 10 Hldgs %
42.45%
Holding
343
New
37
Increased
135
Reduced
115
Closed
13
Avg Time Held
5.2
years
Top 10 Avg Time Held
7.4
years
Top 20 Avg Time Held
6.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gartner
IT
|
+$195M |
| 2 |
MSCI
MSCI
|
+$127M |
| 3 |
Birkenstock
BIRK
|
+$91.8M |
| 4 |
Loar Holdings
LOAR
|
+$84.7M |
| 5 |
Aaon
AAON
|
+$59.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$372M |
| 2 |
Iridium Communications
IRDM
|
+$190M |
| 3 |
Factset
FDS
|
+$158M |
| 4 |
Chart Industries
GTLS
|
+$146M |
| 5 |
Kratos Defense & Security Solutions
KTOS
|
+$138M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 30.84% |
| 2 | Financials | 20.19% |
| 3 | Technology | 18.62% |
| 4 | Real Estate | 8.92% |
| 5 | Healthcare | 8.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
276
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
| $2.22M | 0.01% |
110,000
+10,000
| +10% | +$176K |
2025 Q2
1 quarter
|
|
277
Freshpet
FRPT
$3.2B
| $2.13M | 0.01% |
38,628
+52
| +0.1% | +$3.22K |
2025 Q1
2 quarters
|
|
278
Lumentum
LITE
$74.6B
| $2.05M | 0.01% |
+12,582
| New | +$1.57M |
2025 Q3
0 quarters
|
|
279
Coherent
COHR
$45.9B
| $2.05M | 0.01% |
18,994
+9,792
| +106% | +$976K |
2025 Q2
1 quarter
|
|
280
Vertex Pharmaceuticals
VRTX
$127B
| $2.04M | 0.01% |
5,200
-3,800
| -42% | -$1.59M |
2022 Q2
13 quarters
|
|
281
Doximity
DOCS
$5.52B
| $1.98M | 0.01% |
27,000
+12,000
| +80% | +$782K |
2025 Q2
1 quarter
|
|
282
Robert Half
RHI
$3.41B
| $1.96M | 0.01% |
57,600
| – | – |
2013 Q2
49 quarters
|
|
283
Lam Research
LRCX
$330B
| $1.81M | ﹤0.01% |
13,529
-1,039
| -7% | -$110K |
2022 Q1
14 quarters
|
|
284
Insulet
PODD
$9.79B
| $1.76M | ﹤0.01% |
5,700
| – | – |
2025 Q2
1 quarter
|
|
285
DELISTED
Cidara Therapeutics
CDTX
| $1.68M | ﹤0.01% |
+17,500
| New | +$1.12M |
2025 Q3
0 quarters
|
|
286
Alexandria Real Estate Equities
ARE
$7.16B
| $1.68M | ﹤0.01% |
20,104
-135,902
| -87% | -$10.9M |
2013 Q2
49 quarters
|
|
287
Ionis Pharmaceuticals
IONS
$7.14B
| $1.64M | ﹤0.01% |
+25,000
| New | +$1.22M |
2025 Q3
0 quarters
|
|
288
Progressive
PGR
$127B
| $1.63M | ﹤0.01% |
6,600
-1,400
| -18% | -$345K |
2022 Q2
13 quarters
|
|
289
Alnylam Pharmaceuticals
ALNY
$31B
| $1.6M | ﹤0.01% |
+3,500
| New | +$1.43M |
2025 Q3
0 quarters
|
|
290
Roivant Sciences
ROIV
$24.2B
| $1.59M | ﹤0.01% |
+105,000
| New | +$1.3M |
2025 Q3
0 quarters
|
|
291
UnitedHealth
UNH
$360B
| $1.48M | ﹤0.01% |
+4,300
| New | +$1.3M |
2025 Q3
0 quarters
|
|
292
Manchester United
MANU
$3.51B
| $1.37M | ﹤0.01% |
90,448
| – | – |
2013 Q2
49 quarters
|
|
293
Cytokinetics
CYTK
$8.62B
| $1.35M | ﹤0.01% |
+24,500
| New | +$1.01M |
2025 Q3
0 quarters
|
|
294
DELISTED
Confluent
CFLT
| $1.29M | ﹤0.01% |
65,000
-100,000
| -61% | -$2.09M |
2025 Q1
2 quarters
|
|
295
Blackrock
BLK
$176B
| $1.28M | ﹤0.01% |
1,100
| – | – |
2018 Q1
30 quarters
|
|
296
Xenon Pharmaceuticals
XENE
$3.24B
| $1.2M | ﹤0.01% |
30,000
-26,000
| -46% | -$916K |
2021 Q4
15 quarters
|
|
297
Madrigal Pharmaceuticals
MDGL
$10.4B
| $1.19M | ﹤0.01% |
+2,600
| New | +$970K |
2025 Q3
0 quarters
|
|
298
Novo Nordisk
NVO
$171B
| $1.19M | ﹤0.01% |
21,441
| – | – |
2023 Q4
7 quarters
|
|
299
Abivax
ABVX
$7.69B
| $1.19M | ﹤0.01% |
+14,000
| New | +$858K |
2025 Q3
0 quarters
|
|
300
Ascendis Pharma A/S
ASND
$14.8B
| $1.11M | ﹤0.01% |
+5,600
| New | +$1.04M |
2025 Q3
0 quarters
|
|
Similar funds
BAMCO Inc's Q3 2025 Portfolio in Review
As of Q3 2025, BAMCO Inc held 343 positions worth $37.7B, up 2.2% from $36.9B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
BAMCO Inc's Q3 2025 filing shows 37 new, 135 increased, 115 reduced and 13 closed positions. Its largest new stake was Aaon: 726,907 shares worth $67.9M. The largest sale was Tesla, an estimated $372M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 31% of assets, up from 28% a quarter earlier, followed by Financials and Technology.
- BAMCO Inc's largest Q3 2025 buy was Aaon: 726,907 shares worth $67.9M.
- BAMCO Inc added most to Gartner in Q3 2025, an estimated $195M increase.
- BAMCO Inc's biggest Q3 2025 reduction was Tesla, cutting an estimated $372M.
- BAMCO Inc fully exited Chart Industries in Q3 2025, selling an estimated $146M.
- BAMCO Inc's ten largest holdings make up 42% of its $37.7B portfolio in Q3 2025.
- BAMCO Inc opened 37 new positions and closed 13 in Q3 2025.
- BAMCO Inc's portfolio value rose 2.2% quarter-over-quarter to $37.7B.
Based on BAMCO Inc's 13F filing for Q3 2025, filed 14 Nov 2025.